RU2489154C1 - Method of treating viral hepatites - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gastroenterology, and may be used for treating viral hepatites. Treating viral hepatites involves the interferon therapy. An interferon therapy session is conducted by inhalations of a gas mixture of xenon and oxygen in the concentration of 50:50 to observe the signs of gas exposure - faintness, nystagmus, paresthesia, hyperemia of face, euphoria. The gas mixture is inhaled every second day for 1 month.

EFFECT: invention enables reducing the number of therapeutic complications that is ensured by prevention of stress and depression.

4 cl, 4 ex

Description

The invention relates to medicine and can be used in infectious diseases, gastroenterology, in the treatment of chronic viral hepatitis and their complications.

Existing methods of treating infectious hepatitis using interferons have a wide range of side effects - chills, fever, fatigue, weakness, drowsiness, lethargy, headache, joint and muscle pain, loss of appetite, leukopenia, thrombocytopenia, so the effect is not always achieved with treatment (6, 7, 9).

It is also known that most patients with viral hepatitis are in a state of depression and stress, against this background, the effectiveness of therapy is significantly reduced (6, 7). In addition, the treatment with alpha-interferon in 41% of cases causes depression (6).

A known method of treating viral hepatitis (6) using alpha interferon. The duration of treatment is up to 6 months.

The disadvantage of this method is the presence of complications during treatment in the form of the development of depression, thrombocytopenia, leukopenia, which leads to discontinuation of the course of treatment, and therefore, to a decrease in the effectiveness of the treatment method.

The closest analogue adopted for the prototype is a method in which a combination of alpha-interferon and alpha-fetoprotein (drug profetal) is used. Drugs are administered intramuscularly in the same syringe 1 time per day for 30 days (8).

The use of Profetal helps to reduce the side effect of interferon, there is an improvement in the functional and morphological state of the liver, with good tolerability of treatment.

However, with this method of treatment, complications also arise - depression, thrombocytopenia, leukopenia and a number of others, during the development of which it is necessary to stop therapy, which significantly affects the outcome of treatment.

The problem to which the invention is directed is to increase the effectiveness of hepatitis therapy, reduce the number of complications due to the prevention and treatment of stress and depression.

To solve the problem in a method of treating viral hepatitis, including interferon therapy, according to the invention, an xenon-oxygen mixture is inhaled before an interferon therapy session until there are signs of gas exposure - dizziness, nystagmus, paresthesia, facial flushing, euphoria.

Inhalations begin on the day of initiation of interferon therapy and are administered every other day for 1 month.

Inhalations are carried out with a gas mixture of xenon with oxygen at a concentration of 50:50.

Realderon is used as interferon therapy drugs.

Xenon has a pronounced anti-stress effect. Studies on the use of xenon in the form of inhalation for interferon therapy in a method of treating viral hepatitis have revealed a pronounced antidepressant effect of xenon. Reducing side effects - stress, depression, thrombocytopenia, leukopenia - allows, without interrupting treatment with interferon, to complete the full course of treatment. The effectiveness of treatment is increased and the treatment time for viral hepatitis is reduced.

The inhalation route of administration of xenon is well controlled, it allows you to quickly saturate the body with xenon. Unlike other dosage forms - fat emulsions, tablets with sorbents - it allows using clinical symptoms (euphoria, nystagmus, paresthesia, hyperemia of the skin) to effectively control the course of therapy with a gas mixture of xenon and oxygen.

Example 1. Patient S. 43 years. Complaints of fatigue, decreased performance, appetite, sleep disturbance. Examination revealed an increase in ALT transaminase activity by 2 times, ACT by 1.5 times, total bilirubin 9.6, direct 3.7. In PCR diagnostics, the viral load was 3.2 × 10 ⁶ copies / ml. In a patient, when testing on the Beck Depression scale, severe depression is noted.

Diagnosis: Chronic viral hepatitis C, 2a genotype, minimal degree of activity. Severe depression.

Prescribed treatment: realderon 3 million ME intramuscularly three times a week for 6 months. Inhalation of xenon - with an oxygen gas mixture in a concentration (50:50) every other day for one month (15 inhalations) before the onset of objective and subjective signs of xenon action - dizziness, nystagmus, paresthesia, facial flushing, euphoria.

After the third inhalation, xenon normalized sleep, depression on the Beck scale - moderate. During treatment, leukopenia was not observed, the minimum level of platelets up to 120, white blood cells up to 3.2

One month after the start of treatment. No complaints. There is no depression. Indicators of transaminases ALT, ACT, bilirubin are within normal limits. PCR diagnosis - hepatitis C virus was not detected.

In 6 months. There are no complaints. There are no signs of depression. Indicators of transaminases ALT, ACT, bilirubin are within normal limits. PCR diagnosis - hepatitis C virus was not detected.

Example 2. Patient S. 32 years. Complaints of increased fatigue, periodic weakness, loss of appetite, sleep disturbance. The examination revealed an increase in ALT transaminase activity by 1.5 times, ACT by 2 times, total bilirubin 8.2, direct bilirubin 2.5, indirect - 5.7. In PCR diagnostics, the viral load was 3.2 × 10 ⁶ copies / ml. When testing on the Beck Depression Scale, the patient has moderate depression.

Diagnosis: Chronic viral hepatitis C, 2a genotype, minimal degree of activity. Moderate depression. Prescribed treatment: realderon 3 million ME intramuscularly, prometal at a dose of 150 mcg daily intramuscularly for 30 days. Inhalation of xenon - an oxygen gas mixture in a concentration (50:50) every other day, 15 inhalations. Each inhalation session is conducted before the onset of objective and subjective signs of xenon action in a person, dizziness, nystagmus, paresthesia, facial flushing, euphoria.

After the first xenon inhalation, sleep normalized, the severity of depression on the Beck scale was mild. During treatment, leukopenia was not observed, the minimum level of platelets up to 160, white blood cells up to 3.7. One month after the start of treatment. No complaints. There is no depression. Indicators of transaminases ALT, ACT, bilirubin are within normal limits. PCR diagnosis - hepatitis C virus was not detected.

In 6 months. There are no complaints. There are no signs of depression. Indicators of transaminases ALT, ACT, bilirubin are within normal limits. PCR diagnosis - no hepatitis C virus was detected.

Example 3. Patient S. 37 years. Complaints of increased fatigue, periodic weakness, loss of appetite, sleep disturbance. The examination revealed an increase in the activity of ALT-296 transaminases (7 times), ACT-203 (5 times), total bilirubin 15, 12, direct bilirubin 3.69, indirect - 11.43. In PCR diagnostics, the viral load was 3.9 × 10 ⁶ copies per ml. In a patient, when testing on the Beck Depression scale, severe depression is noted.

Diagnosis: Chronic viral hepatitis C, 1b genotype, low degree of activity degree of activity. Severe depression.

Prescribed treatment: realderon 3 million ME intramuscularly, prometal at a dose of 150 mcg intramuscularly daily for 30 days. Inhalation xenon - an oxygen gas mixture in a concentration (50:50) every other day 15 inhalations. Each inhalation session is conducted before the onset of objective and subjective signs of xenon action - dizziness, nystagmus, paresthesia, facial flushing, euphoria.

After the first xenon inhalation, sleep normalized, mood improved, after the third inhalation the severity of depression on the Beck scale was moderate. During treatment, the minimum platelet count is up to 85, white blood cells up to 3.2 (moderate leukopenia, severe thrombocytopenia).

One month after the start of treatment. No complaints. There is no depression. Indicators of transaminases ALT - 55.8, ACT - 42.8, bilirubin within normal limits. PCR diagnosis - hepatitis C virus was not detected.

In 6 months. There are no complaints. There are no signs of depression. Indicators of transaminases ALT, ACT, bilirubin are within normal limits. PCR diagnosis - hepatitis C virus was not detected.

Patient 4. Z. 32 years. Complaints of fatigue, severe weakness, loss of appetite, sleep disturbance, shortness of breath when walking, joint pain, icteric skin and sclera. According to clinical examination and objective studies, signs of cirrhosis of the liver (hepatosplenomegaly, expansion of the esophagus, hemorrhoidal veins, symptom of a “jellyfish head”, ascites).

The examination revealed an increase in the activity of ALT-169.7 transaminases (3 times), ACT - 238.1 (5 times), total bilirubin 94.7, direct bilirubin 45.46. During PCR diagnosis, the viral load was 4.1 × 10 ⁴ copies per ml. In a patient, when testing on the Beck Depression scale, severe depression is noted.

Diagnosis: Chronic viral hepatitis C, 1b genotype, high activity. Cirrhosis of the liver. Severe depression.

Prescribed treatment: realderon of 3 million ME daily intramuscularly, profetal at a dose of 150 mcg daily intramuscularly for 30 days. Inhalation xenon - an oxygen gas mixture in a concentration (50:50) every other day 15 inhalations. Each inhalation session is conducted before the onset of objective and subjective signs of xenon action, dizziness, nystagmus, paresthesia, facial flushing, euphoria.

After the fourth inhalation, xenon normalized sleep, mood improved, after the sixth inhalation, the severity of depression on the Beck scale was moderate. During treatment - moderate leukopenia, severe thrombocytopenia.

One month after the start of treatment. No complaints. The clinical symptoms of cirrhosis of the liver regressed - hepatosplenomegaly decreased, no ascites, a symptom of a “jellyfish head” could not be determined. There is no depression. Indicators of transaminases ALT - 55.8, ACT - 42.8, bilirubin within normal limits. PCR diagnosis - hepatitis C virus was not detected.

In 6 months. There are no complaints. There are no signs of depression. Indicators of transaminases ALT, ACT, bilirubin are within normal limits. PCR diagnosis - hepatitis C virus was not detected.

The advantages of the claimed invention compared to the prototype are as follows:

- increasing the effectiveness of therapy for viral hepatitis, reducing the number of complications due to the treatment and prevention of stress and depression;

- creating a favorable psychophysiological background during therapy, allowing you to undergo a full course of treatment without interrupting treatment;

- regression of complications of the disease.

Literature

1. Xenon and inert gases in medicine: Materials of the third conference of anaesthesiologists-resuscitators of medical institutions of the Ministry of Defense of the Russian Federation. - M.: GVKG im. N.N. Burdenko, 2012 .-- 136 p.

2. Xenon and inert gases in domestic medicine: Materials of the conference of anaesthesiologists-resuscitators of medical institutions of the Ministry of Defense of the Russian Federation. - M.: GVKG im. N.N. Burdenko, 2010. - 296 p.

3. RF patent No. 2228739. A drug for adaptogenic therapy (options) and a method for its manufacture. MKI ⁶ A61K 9/107, A61K 33/00, A61P 25/00.

4. Naumov S.A., Khlusov I.A. Adaptive effects of xenon. // Intensive care, - 2007. - No. 1. - S.10-16.

5. Anti-innuenze activity of inert gas xenon / Lozitsky V.P., fedchuk A.S., Grydina T.L. // Biomedical and Biosocial Anthropology, - 2010. - No. 15. - P.163-166.

6. Viral hepatitis. Modern aspects of therapy and pharmacoeconomics. Manual for doctors. Sologub T.V., Romantsov M.G., Ketlinskaya O.S., Petrov A.Yu. Academy of Natural Sciences Publishing House, 2008

7. Romantsov M.G., Sologub T.V., Gurenkova N.P. “Triple therapy” of chronic viral hepatitis C in patients with genotype 1b // DOCTOR. - 2006. - No. 7. - S.1-4.

8. RF patent No. 2369403, publ. 10.10.2009, the Method of treatment of chronic viral hepatitis (prototype).

Claims (4)

1. A method of treating viral hepatitis, including interferon therapy, characterized in that before the interferon therapy session, inhalation of a xenon gas mixture with oxygen is performed until signs of exposure to gas occur - dizziness, nystagmus, paresthesia, facial hyperemia, euphoria. 2. The method according to claim 1, characterized in that the inhalation is carried out every other day for 1 month. 3. The method according to claim 1, characterized in that the inhalation is carried out with a gas mixture of xenon with oxygen at a concentration of 50:50. 4. The method according to claim 1, characterized in that realderon is used as an interferon therapy drug.